Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney Transplant
Status:
Withdrawn
Trial end date:
2021-04-15
Target enrollment:
Participant gender:
Summary
This is a proof of concept, single center study for the donation of HCV-positive kidney to
HCV negative recipient patients, with preemptive, interventional treatment with 12 weeks of
commercially available DAA therapy to prevent HCV transmission upon transplantation.